A study on the use of human placental derived stem cells (HPSC) to treat recessive dystrophic epidermolysis bullosa (RDEB).
Phase of Trial: Phase II
Latest Information Update: 24 May 2018
Price : $35 *
At a glance
- Drugs PSC 100 (Primary)
- Indications Epidermolysis bullosa
- Focus Therapeutic Use
- Sponsors Celularity
- 24 May 2018 New trial record
- 17 May 2018 According to a Celularity media release, this study is led by Mitchell Cairo from New York Medical College.